bsm-54427R [Primary Antibody]
Retinoid X Receptor alpha Recombinant Antibody
www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: RXRA

Clonality: Recombinant

Isotype: IgG

Entrez Gene: 6256

Swiss Prot: P19793

Source: Recombinant protein corresponding to N-terminal human Retinoid X Receptor alpha.

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol

Storage: Store at -20°C for 12 months.

Background:

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes.

Size: 100µL

Concentration: Lot Dependent

Applications: WB(1:500-2000)
IP(1:20-50)
Flow-Cyt(1:50-100)
ICC/IF(1:50-200)

Predicted Molecular Weight: 51


Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

25 ug total protein per lane of various lysates (see on figure) probed with Retinoid X Receptor alpha monoclonal antibody, unconjugated (bsm-54427R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.